News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–13
Matches
13
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

13 matching headlines

Ticker or company: FBIOMain company stories
Clear
Latest

nasdaq.com Earnings

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn Jaffe TAKEAWAYS Consolidated Net Revenue -- $18.7 million, representing a 14% increase from $16.4 …

Main company 🇺🇸 United States
Read at nasdaq.com
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
MarketBeat Earnings Main company 🇺🇸 United States

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Earnings Main company 🇺🇸 United States

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
富途牛牛 Earnings Main company 🇺🇸 United States

FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12.

FORTRESS BIOTECH INC (FBIOP.US) is scheduled to release its earnings report after the market closes on August 12. This announcement alerts investors and stakeholders to the upcoming financial disclosure for the company's 9.375% Cumulative Redeemable Preferred Stock Series A.

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Fortress Biotech Inc (FBIO), noting its current valuation score of 7.96, which ranks 108 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is 0.85, significantly above its recent low. It also mentions that relevant …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics successfully closed an oversubscribed $130 million Series B financing round. These funds will support the late-stage global clinical development and commercialization of dotinurad, a URAT1 inhibitor for gout treatment, currently in Phase 2 …

FBIO main company
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6% FBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context